UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2007
INVERNESS MEDICAL
INNOVATIONS, INC.
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Delaware
|
|
1-16789
|
|
04-3565120 |
|
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453
(Address of Principal Executive Offices) (Zip Code)
(781) 647-3900
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
|
| þ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events.
On October 2, 2007, Inverness Medical Innovations, Inc. issued a press release announcing that
the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with
respect to Inverness’ proposed acquisition of HemoSense, Inc. has expired. A copy of this press
release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Press Release, dated October 2, 2007, entitled “Inverness
Medical Innovations and HemoSense Corporation Announce
Expiration of Hart-Scott-Rodino Waiting Period.” |
Additional Information about the Proposed Transaction and Where to Find It:
Inverness has filed with the SEC a registration statement on Form S-4 in connection with the
proposed transaction, which includes HemoSense’s preliminary proxy statement and Inverness’
preliminary prospectus for the proposed transaction. The registration statement has not yet been
declared effective, and a definitive proxy statement/prospectus is not yet available. THE
REGISTRATION STATEMENT AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS WILL CONTAIN IMPORTANT
INFORMATION ABOUT INVERNESS, HEMOSENSE, THE TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE DEFINITIVE PROXY STATEMENT/PROSPECTUS
CAREFULLY WHEN THEY ARE AVAILABLE. Free copies of the registration statement and the proxy
statement/prospectus and other documents filed with the SEC by Inverness and HemoSense can be
obtained through the web site maintained by the SEC at www.sec.gov. In addition, free copies of the
registration statement and the proxy statement/prospectus will be available from Inverness by
contacting Shareholder Relations at (781) 647-3900 or jon.russell@invmed.com or from HemoSense by
contacting Don Markley or Brandi Floberg at 310-691-7100 or bfloberg@lhai.com.
Inverness and its directors and executive officers may be deemed to be participants in the
solicitation of proxies from the shareholders of HemoSense in connection with the proposed
transaction. Information regarding the special interests of these directors and executive officers
in the proposed transaction will be included in the definitive proxy statement/prospectus described
above. Additional information regarding these directors and executive officers is also included in
Inverness’ proxy statement for its 2007 Annual Meeting of Stockholders, which was filed with the
SEC on or about April 9, 2007. This document is available free of charge at the SEC’s web site at
www.sec.gov and from Inverness by contacting Inverness at Shareholder Relations at (781) 647-3900
or jon.russell@invmed.com.
HemoSense and its directors and executive officers also may be deemed to be participants in the
solicitation of proxies from the shareholders of HemoSense in connection with the proposed
transaction. Information regarding the special interests of these directors and executive officers
in the proposed transaction will be included in the definitive proxy statement/prospectus described
above. Additional information regarding these directors and executive officers is also included in
HemoSense’s proxy statement for its 2007 Annual Meeting of Stockholders, which was
filed with the SEC on or about January 29, 2007. This document is available free of charge at the
SEC’s web site at www.sec.gov and from HemoSense by contacting Don Markley or Brandi Floberg at
310-691-7100 or bfloberg@lhai.com.